Genesis Framework R 20.4 A Drift-Modulated Bistable Dynamical Framework for Chronic Disease Stabilization — Pharmacological Compiler Architecture and Structural Stress Test Protocol

AbstractChronic diseases characterized by persistent symptom lock-in — including ME/CFS, Long COVID, rheumatoid arthritis, and neuroinflammatory conditions — present a structural modeling challenge that classical pharmacokinetic/pharmacodynamic frameworks cannot address: patients do not simply have elevated biomarkers, they are captured in a distinct dynamical attractor from which return to baseline is structurally resisted. GENESIS Framework R20. 4 formalizes this observation as a drift-modulated bistable ordinary differential equation system governing three coupled state variables: stress-activation intensity (S), regenerative capacity (R), and accumulated allostatic damage (D). A cubic nonlinear immune activation term S² (1−S) generates genuine multistability with three fixed points (healthy stable node, saddle point, chronic stable node), intrinsic hysteresis, and a functional drift threshold Dfunc = 0. 42 that defines the boundary of therapeutic reversibility without abrupt saddle-node collapse. We extend R20. 4 with a Pharmacological Compiler Architecture that enforces exclusive parameter-transformation-based drug effects — no direct state manipulation is permitted — preserving topological integrity while enabling quantitative attractor landscape modulation. Structural sensitivity analysis across seven free parameters establishes a three-tier leverage hierarchy: Tier-1 topology dominants (regeneration support r0: ΔDfunc = +0. 66; trigger buffer k: ΔDfunc = −1. 05 per ±20% perturbation), Tier-2 basin modulators (sensitization e, damage-regeneration coupling η), and Tier-3 trajectory-only agents (damage repair δ, accumulation rate ε, sensitization amplifier β). The finding that Tier-3 parameters produce zero Dfunc sensitivity at all tested magnitudes — the Delta Paradox — is the central structural result: anti-drift therapies modulate disease progression speed without altering the attractor landscape, making them necessary but insufficient for topological reversal. A Structural Stress Test Protocol (four clinical disease states × eight intervention conditions, 180-day treatment + 180-day washout) demonstrates: topology preservation across all interventions (zero Hopf bifurcations; three fixed points preserved throughout) ; functional irreversibility of trajectory-only modulators confirmed; nonlinear pacing dose-response with topology activation below k × 0. 6; sub-additive combination effects (ΔDfuncTriple = 1. 075 vs. sum-of-singles = 1. 310) attributable to Tier-1 nullcline geometry saturation, suggesting sequential therapy may outperform simultaneous combination; and 96% bistability preservation under triple combination therapy in Monte Carlo robustness testing (N=300, ±20% parameter variation). The framework positions GENESIS R20. 4 as a Topology-Modulating Therapeutic Simulation Framework, conceptually distinct from classical PK/PD models, Boolean network approaches, and empirical outcome predictors. It operationalizes a clinically significant distinction between drugs that restructure the attractor landscape and drugs that only modulate disease trajectory — a distinction with direct implications for therapy stratification, sequential protocol design, and the identification of Dfunc as a novel structural therapeutic endpoint for chronic lock-in diseases.